EFFECT OF TRANSFUSION OF THE THIRD PARTY UMBILICAL CORD BLOOD ON HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
(Abstract release date: 05/19/16)
EHA Library. Jingbo W. 06/09/16; 135069; PB2169
Dr. Wang Jingbo
Contributions
Contributions
Abstract
Abstract: PB2169
Type: Publication Only
Background
Cord blood stem cells have multiple functions in haploidentical stem cell transplantation
Aims
To retrospectively evaluate the effect of the third party umbilical cord blood on haplo-identical hematopoietic stem cell transplantation.
Methods
From June 2012 to May 2015, 125 leukemia patients were enrolled, including 41 cases of ALL, 62cases of AML, 12 cases of MDS, 7 cases of CML-BP, 2 cases of acute mixed leukemia and 1 case of Blastcell dendritic cell tumor. Inclusion criteria: 1) AL patients; 2) halpo-identical HSCT; 3) 3/6 matched cord blood was available. Patients were divided into two groups, ie. groupA (HSCT, n=65) and groupB (HSCT plusumbilical cord blood transfusion group, n=60). Myeloablative conditioning regimens consisted of BuCy, TBI/FLAG, TBI/Cy, and FLAG that followed by reduced-intensified BUCY. The median dose of mononuclear cells in groupA and B were 8.58× 108/kg and 9.01 × 108/kg, respectively. The median dose of CD34+ cells fortransfusion in each group were 3.67 × 106/kg and 2.94 × 106/kg, respectively. The dose of grafted UCB MNCsand CD34+ cells for groupB were 3.5× 107/kg and 2× 105/kg, respectively. All patients received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The endpoints of this study were hematological engraftment,incidence of acute and chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS) in each group.
Results
The median follow-up time was 17(3－29) months in groupA and 18(3－35) months in groupB.Patients in groupA reached a sustained ANC of more than 0.5*109/L at a median of 11 days, whereas 14 daysin groupB. Platelet more than 20*109/L occurred at a median of 19 days in groupA, whereas 17 days in groupB (P= .4). The rate of aGVHD was not significantly different in the two groups, 56.9％ in groupA and 48.3% in groupB (P= .21). The accumulative incidence of II-IV grade aGVHD was 35.4％ in groupA and 30% in groupB (P= .42). The incidence of chronic GVHD was 79.2% in groupA and 71% in groupB (P= .47). The incidence of extensive type was lower in groupB, 69.2% Vs 35% ，P=0.09. The incidence of CMV was lower in groupB, 80% Vs 60% (P= .01). The accumulative incidence of EBV was lower in groupB, 35.4% Vs 3.3% (P<0.01). At two years, the accumulative incidence of relapse was 24.4% in groupA and 17.2% in groupB, P=0.13. The two-year accumulative incidence of OS was 72.9% in groupA and 84.8 ％ in groupB ，P=0.07. The one-year accumulative incidence of DFS in each group were 65.7 ％ and 79.4％，respectively，P=0.03.
Conclusion
Our clinical results have shown that HSCT with transfusion of the third party umbilical cord bloodis a promising modality for induction of immunity reconstitution. Better survival results may benefit from lower incidence of GVHD and virus infection. × 108/kg and 9.01 × 108/kg, respectively. The median dose of CD34+ cells fortransfusion in each group were 3.67 × 106/kg and 2.94 × 106/kg, respectively. The dose of grafted UCB MNCs and CD34+ cells for groupB were 3.5× 107/kg and 2× 105/kg, respectively. All patients received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The endpoints of this study were hematological engraftment,incidence of acute and chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS) in each group.
Session topic: E-poster
Keyword(s): Cord blood, Haploidentical stem cell transplantation
Type: Publication Only
Background
Cord blood stem cells have multiple functions in haploidentical stem cell transplantation
Aims
To retrospectively evaluate the effect of the third party umbilical cord blood on haplo-identical hematopoietic stem cell transplantation.
Methods
From June 2012 to May 2015, 125 leukemia patients were enrolled, including 41 cases of ALL, 62cases of AML, 12 cases of MDS, 7 cases of CML-BP, 2 cases of acute mixed leukemia and 1 case of Blastcell dendritic cell tumor. Inclusion criteria: 1) AL patients; 2) halpo-identical HSCT; 3) 3/6 matched cord blood was available. Patients were divided into two groups, ie. groupA (HSCT, n=65) and groupB (HSCT plusumbilical cord blood transfusion group, n=60). Myeloablative conditioning regimens consisted of BuCy, TBI/FLAG, TBI/Cy, and FLAG that followed by reduced-intensified BUCY. The median dose of mononuclear cells in groupA and B were 8.58× 108/kg and 9.01 × 108/kg, respectively. The median dose of CD34+ cells fortransfusion in each group were 3.67 × 106/kg and 2.94 × 106/kg, respectively. The dose of grafted UCB MNCsand CD34+ cells for groupB were 3.5× 107/kg and 2× 105/kg, respectively. All patients received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The endpoints of this study were hematological engraftment,incidence of acute and chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS) in each group.
Results
The median follow-up time was 17(3－29) months in groupA and 18(3－35) months in groupB.Patients in groupA reached a sustained ANC of more than 0.5*109/L at a median of 11 days, whereas 14 daysin groupB. Platelet more than 20*109/L occurred at a median of 19 days in groupA, whereas 17 days in groupB (P= .4). The rate of aGVHD was not significantly different in the two groups, 56.9％ in groupA and 48.3% in groupB (P= .21). The accumulative incidence of II-IV grade aGVHD was 35.4％ in groupA and 30% in groupB (P= .42). The incidence of chronic GVHD was 79.2% in groupA and 71% in groupB (P= .47). The incidence of extensive type was lower in groupB, 69.2% Vs 35% ，P=0.09. The incidence of CMV was lower in groupB, 80% Vs 60% (P= .01). The accumulative incidence of EBV was lower in groupB, 35.4% Vs 3.3% (P<0.01). At two years, the accumulative incidence of relapse was 24.4% in groupA and 17.2% in groupB, P=0.13. The two-year accumulative incidence of OS was 72.9% in groupA and 84.8 ％ in groupB ，P=0.07. The one-year accumulative incidence of DFS in each group were 65.7 ％ and 79.4％，respectively，P=0.03.
Conclusion
Our clinical results have shown that HSCT with transfusion of the third party umbilical cord bloodis a promising modality for induction of immunity reconstitution. Better survival results may benefit from lower incidence of GVHD and virus infection. × 108/kg and 9.01 × 108/kg, respectively. The median dose of CD34+ cells fortransfusion in each group were 3.67 × 106/kg and 2.94 × 106/kg, respectively. The dose of grafted UCB MNCs and CD34+ cells for groupB were 3.5× 107/kg and 2× 105/kg, respectively. All patients received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The endpoints of this study were hematological engraftment,incidence of acute and chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS) in each group.
Session topic: E-poster
Keyword(s): Cord blood, Haploidentical stem cell transplantation
Abstract: PB2169
Type: Publication Only
Background
Cord blood stem cells have multiple functions in haploidentical stem cell transplantation
Aims
To retrospectively evaluate the effect of the third party umbilical cord blood on haplo-identical hematopoietic stem cell transplantation.
Methods
From June 2012 to May 2015, 125 leukemia patients were enrolled, including 41 cases of ALL, 62cases of AML, 12 cases of MDS, 7 cases of CML-BP, 2 cases of acute mixed leukemia and 1 case of Blastcell dendritic cell tumor. Inclusion criteria: 1) AL patients; 2) halpo-identical HSCT; 3) 3/6 matched cord blood was available. Patients were divided into two groups, ie. groupA (HSCT, n=65) and groupB (HSCT plusumbilical cord blood transfusion group, n=60). Myeloablative conditioning regimens consisted of BuCy, TBI/FLAG, TBI/Cy, and FLAG that followed by reduced-intensified BUCY. The median dose of mononuclear cells in groupA and B were 8.58× 108/kg and 9.01 × 108/kg, respectively. The median dose of CD34+ cells fortransfusion in each group were 3.67 × 106/kg and 2.94 × 106/kg, respectively. The dose of grafted UCB MNCsand CD34+ cells for groupB were 3.5× 107/kg and 2× 105/kg, respectively. All patients received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The endpoints of this study were hematological engraftment,incidence of acute and chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS) in each group.
Results
The median follow-up time was 17(3－29) months in groupA and 18(3－35) months in groupB.Patients in groupA reached a sustained ANC of more than 0.5*109/L at a median of 11 days, whereas 14 daysin groupB. Platelet more than 20*109/L occurred at a median of 19 days in groupA, whereas 17 days in groupB (P= .4). The rate of aGVHD was not significantly different in the two groups, 56.9％ in groupA and 48.3% in groupB (P= .21). The accumulative incidence of II-IV grade aGVHD was 35.4％ in groupA and 30% in groupB (P= .42). The incidence of chronic GVHD was 79.2% in groupA and 71% in groupB (P= .47). The incidence of extensive type was lower in groupB, 69.2% Vs 35% ，P=0.09. The incidence of CMV was lower in groupB, 80% Vs 60% (P= .01). The accumulative incidence of EBV was lower in groupB, 35.4% Vs 3.3% (P<0.01). At two years, the accumulative incidence of relapse was 24.4% in groupA and 17.2% in groupB, P=0.13. The two-year accumulative incidence of OS was 72.9% in groupA and 84.8 ％ in groupB ，P=0.07. The one-year accumulative incidence of DFS in each group were 65.7 ％ and 79.4％，respectively，P=0.03.
Conclusion
Our clinical results have shown that HSCT with transfusion of the third party umbilical cord bloodis a promising modality for induction of immunity reconstitution. Better survival results may benefit from lower incidence of GVHD and virus infection. × 108/kg and 9.01 × 108/kg, respectively. The median dose of CD34+ cells fortransfusion in each group were 3.67 × 106/kg and 2.94 × 106/kg, respectively. The dose of grafted UCB MNCs and CD34+ cells for groupB were 3.5× 107/kg and 2× 105/kg, respectively. All patients received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The endpoints of this study were hematological engraftment,incidence of acute and chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS) in each group.
Session topic: E-poster
Keyword(s): Cord blood, Haploidentical stem cell transplantation
Type: Publication Only
Background
Cord blood stem cells have multiple functions in haploidentical stem cell transplantation
Aims
To retrospectively evaluate the effect of the third party umbilical cord blood on haplo-identical hematopoietic stem cell transplantation.
Methods
From June 2012 to May 2015, 125 leukemia patients were enrolled, including 41 cases of ALL, 62cases of AML, 12 cases of MDS, 7 cases of CML-BP, 2 cases of acute mixed leukemia and 1 case of Blastcell dendritic cell tumor. Inclusion criteria: 1) AL patients; 2) halpo-identical HSCT; 3) 3/6 matched cord blood was available. Patients were divided into two groups, ie. groupA (HSCT, n=65) and groupB (HSCT plusumbilical cord blood transfusion group, n=60). Myeloablative conditioning regimens consisted of BuCy, TBI/FLAG, TBI/Cy, and FLAG that followed by reduced-intensified BUCY. The median dose of mononuclear cells in groupA and B were 8.58× 108/kg and 9.01 × 108/kg, respectively. The median dose of CD34+ cells fortransfusion in each group were 3.67 × 106/kg and 2.94 × 106/kg, respectively. The dose of grafted UCB MNCsand CD34+ cells for groupB were 3.5× 107/kg and 2× 105/kg, respectively. All patients received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The endpoints of this study were hematological engraftment,incidence of acute and chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS) in each group.
Results
The median follow-up time was 17(3－29) months in groupA and 18(3－35) months in groupB.Patients in groupA reached a sustained ANC of more than 0.5*109/L at a median of 11 days, whereas 14 daysin groupB. Platelet more than 20*109/L occurred at a median of 19 days in groupA, whereas 17 days in groupB (P= .4). The rate of aGVHD was not significantly different in the two groups, 56.9％ in groupA and 48.3% in groupB (P= .21). The accumulative incidence of II-IV grade aGVHD was 35.4％ in groupA and 30% in groupB (P= .42). The incidence of chronic GVHD was 79.2% in groupA and 71% in groupB (P= .47). The incidence of extensive type was lower in groupB, 69.2% Vs 35% ，P=0.09. The incidence of CMV was lower in groupB, 80% Vs 60% (P= .01). The accumulative incidence of EBV was lower in groupB, 35.4% Vs 3.3% (P<0.01). At two years, the accumulative incidence of relapse was 24.4% in groupA and 17.2% in groupB, P=0.13. The two-year accumulative incidence of OS was 72.9% in groupA and 84.8 ％ in groupB ，P=0.07. The one-year accumulative incidence of DFS in each group were 65.7 ％ and 79.4％，respectively，P=0.03.
Conclusion
Our clinical results have shown that HSCT with transfusion of the third party umbilical cord bloodis a promising modality for induction of immunity reconstitution. Better survival results may benefit from lower incidence of GVHD and virus infection. × 108/kg and 9.01 × 108/kg, respectively. The median dose of CD34+ cells fortransfusion in each group were 3.67 × 106/kg and 2.94 × 106/kg, respectively. The dose of grafted UCB MNCs and CD34+ cells for groupB were 3.5× 107/kg and 2× 105/kg, respectively. All patients received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The endpoints of this study were hematological engraftment,incidence of acute and chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS) in each group.
Session topic: E-poster
Keyword(s): Cord blood, Haploidentical stem cell transplantation
{{ help_message }}
{{filter}}